Project Grant R35HL177381
Award Date
6/5/25
Completion Date
5/31/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Louisiana, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $880,735 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Washington. The funding supports research to investigate how cell lysis and release of leukotrienes activate type-2 immunity in the lung. Key objectives include identifying alveolar macrophages as a source of leukotriene C4, examining the roles of leukotrienes in regulating innate lymphoid cell function and downstream...
The University of Tennessee Health Science Center received a $615,455 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective September 1, 2024 through June 30, 2028, supports research to investigate the role of eosinophils in promoting antibacterial immunity against Streptococcus pneumoniae, a leading cause of bacterial pneumonia that often co-occurs with influenza infections. The...
This $163,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multidimensional analysis of the regulatory T cell (Treg) response in children with severe viral pneumonia. The primary investigator will conduct research to determine if Treg cells have impaired reparative functions during severe viral pneumonia in juvenile mice, investigate how the age-specific lung microenvironment affects...
This $342,900 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to define the functional role of lung microfold (M) cells in predisposition to influenza-associated pneumococcal invasion and resulting pneumonia and sepsis. The research aims to identify the intracellular trafficking mechanisms during pneumococcal transcytosis across airway M cells. The work will be conducted at the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on the mechanisms underlying lung injury, fibrosis, and susceptibility to bacterial infections. The key objectives are to study: 1) how epithelial cell signaling regulates fibrosis and interacts with myeloid cells, 2) the impaired innate immunity against...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,446 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Washington University to conduct research on the spatiotemporal control of early matricellular events in the injured lung. The research aims to better understand how the matricellular protein thrombospondin-1 (TSP1) regulates the formation and stabilization of the provisional extracellular matrix during acute lung injury, with the goal...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
The University of North Carolina at Chapel Hill (UNC-CH) received a $759,983 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research examining the mechanisms underlying the diverse responses of neutrophils during Streptococcus pneumoniae pneumonia and acute lung injury. The project aims to determine the changes that neutrophils undergo as they are recruited and perform their...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $684,814 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how lung stromal factors modify the inflammatory response to viral infections and tobacco smoke, and how tissue-resident lymphocytes can...
This federal Project Grant award of $626,956.00 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of tRNA- and rRNA-derived small non-coding RNAs (sncRNAs) in the pathogenesis of acute lung injury (ALI). The grant aims to leverage advanced RNA sequencing techniques developed by the researchers to comprehensively characterize the dysregulation of these "hidden" sncRNAs,...